section name header

Pronunciation

i-MI-kwi-mod

Classifications

Therapeutic Classification: antivirals, immune modifiers

Pharmacologic Classification: immune response modifiers

Indications

REMS


Action

  • May induce the formation of interferons that have antiproliferative and antiviral properties.
Therapeutic effects:
  • Regression of external genital or perianal warts/condylomata, actinic keratoses, or basal cell carcinoma lesions.

Pharmacokinetics

Absorption: Minimal absorption.

Distribution: Action is primarily local.

Metabolism/Excretion: <0.9% excreted in urine and feces.

Half-Life: Unknown.

Time/Action Profile

(regression of lesions)

ROUTEONSETPEAKDURATION
Topicaldays–wk10–16 wkunknown



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: diarrhea, nausea

GU: dysuria, vulvar swelling

Local: irritation, pain, pruritus, burning, swelling, fungal infections (women)

Neuro: dizziness, fatigue, headache

Interactions

Drug-drug:

Route/Dosage

External Genital Warts

Actinic Keratoses

Superficial Basal Cell Carcinoma

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Zyclara

Canadian Brand Names

Aldara P, Vyloma

Code

NDC Code